Dabrafenib instructions, indications, usage and dosage, side effects

1. Indications

Dabrafenib (trade name: TAFINLAR) is a kinase inhibitor mainly used to treat BRAF V600 mutation-positive unresectable or metastatic melanoma. In addition, it can also be used in combination with trametinib to treat patients with BRAF V600 mutation-positive unresectable or metastatic melanoma, as well as for postoperative adjuvant treatment of BRAF V600 mutation-positive melanoma. In some cases, it is also used to treat BRAF V600 mutation-positive metastatic non-small cell lung cancer.

2. Usage and dosage

The recommended dose of dabrafenib is 150 mg twice daily, approximately 12 hours apart. It should be taken at least 1 hour before or 2 hours after a meal. When used in combination with trametinib, the recommended dose of trametinib is 2 mg orally once daily, given at the same time as dabrafenib or in the morning. Treatment should be continued until disease progression or unacceptable toxicity occurs.

3. Side effects

Dabrafenib may cause a range of side effects during use. When used as a single agent, the most common adverse reactions (incidence >20%) include keratoderma, headache, pyrexia, arthralgia, papilloma, alopecia, and palmoplantar erythrodysesthesia syndrome (PPES). When used concomitantly with trametinib, the most common adverse reactions (incidence >20%) include pyrexia, rash, chills, fatigue, nausea, vomiting, diarrhea, abdominal pain, peripheral edema, cough, headache, arthralgia, night sweats, decreased appetite, constipation, and myalgia.

Some serious side effects may also occur, including new malignancies, bleeding, venous thrombosis, cardiomyopathy, ocular toxicity, severe febrile reactions, severe skin toxicity, and hyperglycemia. Get immediate medical attention if you develop allergic reactions, high blood sugar, signs of bleeding, electrolyte problems, kidney problems, erythema multiforme/toxic epidermal necrolysis, or other serious adverse reactions.

4. Precautions

Patients with hepatic impairment: No dose adjustment is required in patients with mild hepatic impairment, but this product should be used with caution in patients with moderate or severe hepatic impairment.

Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment, but this product should be used with caution in patients with severe renal impairment.

Pregnant and breastfeeding women: Pregnant women should not take dabrafenib because it may cause damage to the fetus. Breastfeeding women should avoid breastfeeding while taking the drug and for 16 weeks after stopping the drug.

Women of childbearing age and male patients: Effective contraceptive measures should be used during treatment and for at least 2 weeks after the end of treatment.

Drug interactions: When dabrafenib is combined with certain drugs, such as strong inhibitors or inducers of CYP3A4 or CYP2C8, it may cause the drug concentration to increase or decrease, thus affecting efficacy and safety. Therefore, concomitant administration of these drugs should be avoided, and if unavoidable, patients should be closely monitored for adverse reactions and efficacy.

Skin examination: Because dabrafenib may cause skin problems such as squamous cell carcinoma of the skin, skin examinations should be performed regularly while you are taking it.

5. Storage and validity period

Dabrafenib should be stored in a dark, airtight, dry place below 30°C. After unsealing, it must be stored in the original packaging with desiccant. Its validity period is 24 months.

Dabrafenib is an effective anti-tumor drug, but its side effects and precautions need to be paid close attention to during use to ensure patient safety and therapeutic effect. If you have any questions or discomfort, you should consult a doctor in time and take appropriate treatment measures.